Immunic shares soar 48% after-hours buoyed by interim MS data
Shares in Immunic Inc (NASDAQ:IMUX) soared 48% in after-hours trading following the release of encouraging interim data from its phase II CALLIPER trial...
Stay updated with breaking news from Immunic Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Shares in Immunic Inc (NASDAQ:IMUX) soared 48% in after-hours trading following the release of encouraging interim data from its phase II CALLIPER trial...
Immunic Inc (NASDAQ: IMUX) announced interim data from its phase 2 CALLIPER trial of nuclear receptor-related 1 (Nurr1) activator, vidofludimus calcium (IMU-838), in patients with
Gainers SuperCom Ltd. (NASDAQ: SPCB) shares rose 78.4% to $0.6425 in pre-market trading, after falling 13% on Monday.
– 24-Week Data from First Half of Patients Shows Improvements in Biomarker NfL, Consistent Throughout the Overall Progressive Multiple Sclerosis P...
/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for...